{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:29:21Z","timestamp":1790342961966,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G085920N"],"award-info":[{"award-number":["G085920N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S59522N"],"award-info":[{"award-number":["1S59522N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1881020N"],"award-info":[{"award-number":["1881020N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1186\/s13613-023-01129-6","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T09:02:29Z","timestamp":1682758949000},"page":"35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-6640","authenticated-orcid":false,"given":"Thomas","family":"De Corte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-150X","authenticated-orcid":false,"given":"Jarne","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-7167","authenticated-orcid":false,"given":"Sofie","family":"Dhaese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7278-1895","authenticated-orcid":false,"given":"Sarah","family":"Van Vooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2282-8194","authenticated-orcid":false,"given":"Jerina","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-3315","authenticated-orcid":false,"given":"Alain","family":"G. Verstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-971X","authenticated-orcid":false,"given":"Veronique","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2529-5477","authenticated-orcid":false,"given":"Femke","family":"Ongenae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-5857","authenticated-orcid":false,"given":"Liesbet","family":"De Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-5376","authenticated-orcid":false,"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-6793","authenticated-orcid":false,"given":"Sofie","family":"Van Hoecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1017-9748","authenticated-orcid":false,"given":"Jan","family":"J. De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1186\/s13613-023-01129-6_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13054-018-2178-7","article-title":"A complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration","volume":"22","author":"De Bus","year":"2018","journal-title":"Crit Care"},{"issue":"15","key":"10.1186\/s13613-023-01129-6_bb0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1186\/s13613-023-01129-6_bb0020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01129-6_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1186\/s13613-023-01129-6_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"issue":"10","key":"10.1186\/s13613-023-01129-6_bb0035","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically Ill patients: a systematic review and meta-analysis","volume":"75","author":"Pai Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01129-6_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchromb.2014.11.034","article-title":"Ultrafast quantification of \u03b2-lactam antibiotics in human plasma using UPLC-MS\/MS","volume":"978\u2013979","author":"Carlier","year":"2015","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1186\/s13613-023-01129-6_bb0045","unstructured":"Wyeth Piperacillin Division of Wyeth Holdings Corporation, a subsidiary of Pfizer. ZOSYN- tazobactam sodium and piperacillin sodium injection, powder, lyophilized, for solution. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=502. Accessed 8 Jan 2022."},{"key":"10.1186\/s13613-023-01129-6_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/clinids\/24.Supplement_2.S266","article-title":"The pharmacology of meropenem, a new carbapenem antibiotic","author":"Craig","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01129-6_bb0055","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s10916-012-9849-8","article-title":"COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU","volume":"36","author":"Steurbaut","year":"2012","journal-title":"J Med Syst"},{"issue":"1","key":"10.1186\/s13613-023-01129-6_bb0060","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1186\/s13613-023-01129-6_bb0065","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"10.1186\/s13613-023-01129-6_bb0070","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1186\/s13613-023-01129-6_bb0075","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST): Clinical breakpoints and dosing of antibiotics. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 25 Jan 2022."},{"key":"10.1186\/s13613-023-01129-6_bb0080","unstructured":"Comit\u00e9 de l\u2019Antibiograme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. https:\/\/www.sfm-microbiologie.org\/boutique\/comite-de-lantibiograme-de-la-sfm-casfm\/. Accessed Jan 25 2022."},{"issue":"9","key":"10.1186\/s13613-023-01129-6_bb0085","doi-asserted-by":"crossref","first-page":"e00654","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01129-6_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/antibiotics9030131","article-title":"Therapeutic drug monitoring of meropenem and Piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01129-6_bb0095","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA: RStudio, PBC; 2022. https:\/\/support.posit.co\/hc\/en-us\/articles\/206212048-Citing-RStudio."},{"issue":"6","key":"10.1186\/s13613-023-01129-6_bb0100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"issue":"7","key":"10.1186\/s13613-023-01129-6_bb0105","doi-asserted-by":"crossref","first-page":"e02556","DOI":"10.1128\/AAC.02556-19","article-title":"Population pharmacokinetics of piperacillin following continuous infusion in critically ill patients and impact of renal function on target attainment","volume":"64","author":"Klastrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"e1","key":"10.1186\/s13613-023-01129-6_bb0110","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1136\/ejhpharm-2018-001713","article-title":"Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients","volume":"27","author":"Schoenenberger-Arnaiz","year":"2020","journal-title":"Eur J Hosp Pharm"},{"issue":"67","key":"10.1186\/s13613-023-01129-6_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcrc.2021.10.023","article-title":"\u03b2-lactam dosing at the early phase of sepsis: performance of a pragmatic protocol for target concentration achievement in a prospective cohort study","volume":"1","author":"Winiszewski","year":"2022","journal-title":"J Crit Care"},{"issue":"68","key":"10.1186\/s13613-023-01129-6_bb0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcrc.2021.12.013","article-title":"Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population\u2014A prospective, multi-center, observational study (BLAST 1)","volume":"1","author":"Chua","year":"2022","journal-title":"J Crit Care"},{"issue":"6","key":"10.1186\/s13613-023-01129-6_bb0125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/antibiotics11060758","article-title":"Evaluation of a meropenem and piperacillin monitoring program in intensive care unit patients calls for the regular assessment of empirical targets and easy-to-use dosing decision tools","volume":"11","author":"Weinelt","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1186\/s13613-023-01129-6_bb0130","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12879-020-05149-6","article-title":"Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis","volume":"20","author":"Fawaz","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1186\/s13613-023-01129-6_bb0135","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/antibiotics10111311","article-title":"Assessment of a PK\/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented gram-negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiotics"},{"issue":"11","key":"10.1186\/s13613-023-01129-6_bb0140","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? Systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1186\/s13613-023-01129-6_bb0145","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/antibiotics11070889","article-title":"Why we may need higher doses of beta-lactam antibiotics: introducing the \u2018maximum tolerable dose","volume":"11","author":"Dhaese","year":"2022","journal-title":"Antibiotics"},{"key":"10.1186\/s13613-023-01129-6_bb0150","unstructured":"Meropenem_Rationale_Document_2.0_20210101.pdf. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Meropenem_Rationale_Document_2.0_20210101.pdf. Accessed 13 Mar 2023."},{"key":"10.1186\/s13613-023-01129-6_bb0155","first-page":"1","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"9","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1186\/s13613-023-01129-6_bb0160","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01129-6_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/FTD.0000000000000602","article-title":"Measuring unbound versus total piperacillin concentrations in plasma of critically ill patients: methodological issues and relevance","volume":"41","author":"Colman","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1186\/s13613-023-01129-6_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","article-title":"Meropenem, cefepime, and piperacillin protein binding in patient samples","volume":"42","author":"Al-Shaer","year":"2020","journal-title":"Ther Drug Monit"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-023-01129-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:35:44Z","timestamp":1776670544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025003620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2110582025003620"],"URL":"https:\/\/doi.org\/10.1186\/s13613-023-01129-6","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-023-01129-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s) 2023. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"35"}}